Early attainment of isavuconazole target concentration using an increased loading dose in critically ill patients with extracorporeal membrane oxygenation

Population Pharmacokinetics of Isavuconazole in Critical Care Patients with COVID-19-Associated Pulmonary Aspergillosis and Monte Carlo Simulations of High Off-Label Doses

(2023) Lucas Perez et al.   Journal of Fungi

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Isavuconazonium Sulfate in Healthy Adult Japanese Subjects

(2022) Shinichiro Shirae et al.   Clinical Pharmacology in Drug Development

Decreased isavuconazole trough concentrations in the treatment of invasive aspergillosis in an adult patient receiving extracorporeal membrane oxygenation support

(2022) Michelle Miller et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Isavuconazole therapeutic drug monitoring in critically ill ICU patients: A monocentric retrospective analysis

(2022) Rainer Höhl et al.   MYCOSES

Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation

(2022) Lisa Kriegl et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

COVID-19-associated fungal infections

(2022) Martin Hoenigl et al.   Nature Microbiology

Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation—authors’ response

(2022) Stefan Hatzl et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comment on: Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation

(2022) Beatrijs Mertens et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group

(2021) Matteo Bassetti et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation

(2021) Ruth Van Daele et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial

(2021) Lore Vanderbeke et al.   INTENSIVE CARE MEDICINE

A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation

(2021) Ruth Van Daele et al.   Microorganisms

Implementation of a Dual-Column Liquid Chromatography-Tandem Mass-Spectrometry Method for the Quantification of Isavuconazole in Clinical Practice

(2021) Dietmar Enko et al.   Journal of Laboratory Physicians

Isavuconazole Treatment in a Mixed Patient Cohort with Invasive Fungal Infections: Outcome, Tolerability and Clinical Implications of Isavuconazole Plasma Concentrations

(2020) Christoph Zurl et al.   Journal of Fungi

Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance

(2020) Philipp Koehler et al.   LANCET INFECTIOUS DISEASES

Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy

(2019) E Furfaro et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Inter-laboratory analysis of Isavuconazole plasma concentration assays among European laboratories

(2019) Federico Pea et al.   THERAPEUTIC DRUG MONITORING

The REDCap consortium: Building an international community of software platform partners

(2019) Paul A. Harris et al.   JOURNAL OF BIOMEDICAL INFORMATICS

Defining breakthrough invasive fungal infection–Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology

(2019) Oliver A. Cornely et al.   MYCOSES

Population Pharmacokinetics of Intravenous Isavuconazole in Solid Organ Transplant Recipients

(2019) Xuemei Wu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium

(2019) Oliver A Cornely et al.   LANCET INFECTIOUS DISEASES

Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials

(2018) David Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study

(2018) Alexander F A D Schauwvlieghe et al.   Lancet Respiratory Medicine

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials

(2018) David R. Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Variability and exposure–response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases

(2018) Thomas Kaindl et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi

(2016) Amit Desai et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

(2016) Thomas F. Patterson et al.   CLINICAL INFECTIOUS DISEASES

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients

(2016) Frederic Tissot et al.   HAEMATOLOGICA

Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection

(2016) Francesco Barchiesi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

(2016) Johan A Maertens et al.   LANCET

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients

(2016) Frederic Tissot et al.   HAEMATOLOGICA

Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent

(2015) Jeffrey M. Rybak et al.   PHARMACOTHERAPY

A Clinical Algorithm to Diagnose Invasive Pulmonary Aspergillosis in Critically Ill Patients

(2012) Stijn I. Blot et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation

(2009) I. Spriet et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria

(2008) Brahm H. Segal et al.   CLINICAL INFECTIOUS DISEASES

Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation

(2008) Stéphanie Ruiz et al.   INTENSIVE CARE MEDICINE